---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004057"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:30:04.214273+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dyne reports $642M cash, positive DYNE-101 DM1 data, H1 2026 submission path

## Summary
- Preliminary cash, equivalents, and marketable securities ~$642M as of Dec 31, 2024 (unaudited).
- DYNE-101 in DM1: 6.8 mg/kg Q8W dose showed robust splicing correction at 3 months and sustained functional improvements.
- DYNE-101 safety: 855 doses administered, >72 patient-years follow-up; no related serious TEAEs.
- Plans ~32-patient Registrational Expansion Cohort for DYNE-101 in mid-2025; U.S. accelerated approval submission targeted H1 2026.
- DYNE-251 for DMD exon 51: FDA supports dystrophin as surrogate endpoint; data from 20 mg/kg cohort expected late 2025.

## SEC filing metadata
- accession: 0001193125-25-004057
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000119312525004057/0001193125-25-004057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000119312525004057/d909941d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004057
- JSON: https://secwatch.observer/filing/0001193125-25-004057.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.